caa a22 4500 477127541 CHVBK 20180405111654.0 cr unu---uuuuu 170330e19970401xx s 000 0 eng 10.1023/A:1012022810550 doi (NATIONALLICENCE)springer-10.1023/A:1012022810550 Guanidine Transport in a Human Choriocarcinoma Cell Line (JAR) [Elektronische Daten] [Shoshana Zevin, Marci Schaner, Nicholas Illsley, Kathleen Giacomini] Purpose. Many endogenous substances and xenobiotics are organic cations. Transplacental transport of organic cations is an important determinant of the delivery of these compounds to the fetus. The aim of this study was to determine the mechanisms of organic cation transport using the human choriocarcinoma cell line (JAR) as a model system with [14C]guanidine as a ligand. Methods. Uptake studies of [l4C]guanidine were carried out in JAR cell monolayers on day 2 after plating. Results. [14C]guanidine uptake was temperature dependent, saturable (Km = 167 μM) and inhibited by many organic cations including amiloride, cimetidine, quinine, quinidine and nicotine. [l4C]guanidine uptake exhibited a counterflux phenomenon indicative of a carrier-mediated process. The uptake of [14C]guanidine was sodium and pH-independent and could be driven by an inside-negative membrane potential difference. Conclusions. This is the first demonstration of an electrogenic guanidine transporter in a human cell culture model. This transporter may play a role in the transplacental transport of many clinically used drugs and xenobiotics. Plenum Publishing Corporation, 1997 organic cation transport nationallicence placenta nationallicence guanidine nationallicence JAR cells nationallicence Zevin Shoshana Division of Clinical Pharmacology and Experimental Therapeutics and Department of Biopharmaceutical Sciences, University of California San Francisco, 94143, San Francisco, California aut Schaner Marci Division of Clinical Pharmacology and Experimental Therapeutics and Department of Biopharmaceutical Sciences, University of California San Francisco, 94143, San Francisco, California aut Illsley Nicholas Department of Obstetrics and Gynecology, University of Medicine and Dentistry New Jersey, USA aut Giacomini Kathleen Division of Clinical Pharmacology and Experimental Therapeutics and Department of Biopharmaceutical Sciences, University of California San Francisco, 94143, San Francisco, California aut Pharmaceutical Research Kluwer Academic Publishers-Plenum Publishers 14/4(1997-04-01), 401-405 0724-8741 14:4<401 1997 14 11095 https://doi.org/10.1023/A:1012022810550 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1012022810550 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zevin Shoshana Division of Clinical Pharmacology and Experimental Therapeutics and Department of Biopharmaceutical Sciences, University of California San Francisco, 94143, San Francisco, California aut NATIONALLICENCE 700 1- Schaner Marci Division of Clinical Pharmacology and Experimental Therapeutics and Department of Biopharmaceutical Sciences, University of California San Francisco, 94143, San Francisco, California aut NATIONALLICENCE 700 1- Illsley Nicholas Department of Obstetrics and Gynecology, University of Medicine and Dentistry New Jersey, USA aut NATIONALLICENCE 700 1- Giacomini Kathleen Division of Clinical Pharmacology and Experimental Therapeutics and Department of Biopharmaceutical Sciences, University of California San Francisco, 94143, San Francisco, California aut NATIONALLICENCE 773 0- Pharmaceutical Research Kluwer Academic Publishers-Plenum Publishers 14/4(1997-04-01), 401-405 0724-8741 14:4<401 1997 14 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer